Study Design.: Retrospective administrative database study. Objective.: To assess temporal and regional trends, and length of hospital stay, in lumbar spinal stenosis (LSS) surgery in Norwegian public hospitals from 1999 to 2013. Summary of Background Data.: Studies from several countries have reported increasing rates of LSS surgery over the last decades. No such data have been presented from Norway. Methods.: A database consisting of discharges from all Norwegian public hospitals was established. Inclusion criteria were discharges including a surgical procedure of lumbar spinal decompression and/or fusion in combination with an International Statistical Classification of Diseases and Related Health Problems, 10th Revision diagnosis of Spinal Stenosis (M48.0) or Other Spondylosis with Radiculopathy (M47.2), and a patient age of 18 years or older. Discharges with diagnoses indicating deformity, that is, spondylolisthesis or scoliosis were not included. Results.: During the 15-year period, 19,543 discharges were identified. The annual rate of decompressions increased from 10.7 to 36.2 and fusions increased from 2.5 to 4.4 per 100,000 people of the general Norwegian population. The proportion of fusion surgery decreased from 19.3% to 10.9%. Among individuals older than 65 years, the annual rate of surgery per 10,000, including both decompressions and fusions, more than quadrupled from 40.2 to 170.3. The regional variation was modest, differing with a factor of 1.4 between the region with the highest and the lowest surgical rates. The mean length of hospital stay decreased from 11.0 (standard deviation 8.0) days in 1999 to 5.0 (4.6) days in 2013, but patients who received fusion surgery stayed on average 3.6 days longer than those who received decompression only. Conclusion.: The rate of LSS surgery more than tripled in Norway from 1999 to 2013. The mean length of hospital stay was reduced from 11 to 5 days. Level of Evidence: N/A
Cross-sectional and prospective study of patients with sciatica and disc herniation. To describe the process of translation of the Norwegian versions of the Maine Seattle Back Questionnaire (MSBQ), the Sciatica Bothersomeness Index (SBI) and the Sciatica Frequency Index (SFI), and to test the reliability, construct validity and responsiveness of these Norwegian versions. The instruments have been validated in English only. Reliability was assessed by internal consistency (Cronbach alpha), test-retest reliability (ICC) and measurement error (MDC and Bland and Altman's limits of agreement). Construct validity was assessed by comparing the 3 measures with subscales of SF-36, ratings of back and leg pain, and clinical findings. Responsiveness was assessed by standardized response means and Receiver Operating Characteristic curve analyses. Four hundred sixty six patients were included in the study, of whom 87 participated in the test-retest study. Completion time for the MSBQ was 1-2 minutes and 30 seconds for the SBI and the SFI, respectively. ICCs varied between 0.86 and 0.90. Cronbach alpha was 0.74, 0.70, and 0.65 for the MSBQ, SBI, and SFI, respectively. The measurement errors constituted 26% of the total MSBQ score range, 22% of the SBI and 27% of the SFI score range. Compared to the MSBQ the 2 Sciatica Indexes discriminated better between patients with normal versus abnormal clinical findings, but correlated less strongly with pain and physical functioning. Responsiveness was assessed by 2 external criteria at 3 months, a global change score (improved vs. unchanged) and surgical treatment status (operated vs. nonoperated). All standardized response means were >or=1.3 and all AUCs >or=0.75. Differences between the 3 measures were generally small. The Norwegian versions of the MSBQ and the Sciatica Frequency and Bothersomeness Indexes were rapidly administered, with acceptable internal consistency, test-retest reliability, measurement error, construct validity and responsiveness.
Previous studies suggest that regulatory microRNAs (miRs) may modulate neuro-inflammatory processes. The purpose of the present study was to examine the role of miR-17 following intervertebral disc herniation. In a cohort of 97 patients with leg pain and disc herniation verified on MRI, we investigated the association between circulating miR-17 and leg pain intensity. A rat model was used to examine possible changes in miR-17 expression in nucleus pulposus (NP) associated with leak of NP tissue out of the herniated disc. The functional role of miR-17 was addressed by transfection of miR-17 into THP-1 cells (human monocyte cell line). An association between the level of miR-17 in serum and the intensity of lumbar radicular pain was shown. Up-regulation of miR-17 in the rat NP tissue when applied onto spinal nerve roots and increased release of TNF following transfection of miR-17 into THP-1 cells were also observed. Hence, our data suggest that miR-17 may be involved in the pathophysiology underlying lumbar radicular pain after disc herniation. We conclude that miR-17 may be associated with the intensity of lumbar radicular pain after disc herniation, possibly through a TNF-driven pro-inflammatory mechanism.
Background: Low back pain is common and a significant number of patients experience chronic low back pain. Current treatment options offer small to moderate effects. Patients with vertebral bone marrow lesions visualized as Modic changes on magnetic resonance imaging may represent a subgroup within the low back pain population. There is evidence for inflammatory mediators being involved in development of Modic changes; hence, suppression of inflammation could be a treatment strategy for these patients. This study examines the effect of anti-inflammatory treatment with the TNF-α inhibitor infliximab in patients with chronic low back pain and Modic changes. Methods/design: The BackToBasic trial is a multicenter, double blind, randomized controlled trial conducted at six hospitals in Norway, comparing intravenous infusions with infliximab with placebo. One hundred twenty-six patients aged 18–65 with chronic low back pain and type 1 Modic changes will be recruited from secondary care outpatients’ clinics. The primary outcome is back pain-specific disability at day 154 (5 months). The study is designed to detect a difference in change of 10 (SD 18) in the Oswestry Disability Index at day 154/ 5 months. The study also aims to refine MRI-assessment, investigate safety and cost-effectiveness and explore the underlying biological mechanisms of Modic changes. Discussion: Finding treatments that target underlying mechanisms could pose new treatment options for patients with low back pain. Suppression of inflammation could be a treatment strategy for patients with low back pain and Modic changes. This paper presents the design of the BackToBasic study, where we will assess the effect of an anti-inflammatory treatment versus placebo in patients with chronic low back pain and type 1 Modic changes. The study is registered at ClinicalTrials.gov under the identifier NCT03704363. The EudraCT Number: 2017–004861-29.